Advertisement

Single Nucleotide Polymorphism and Moyamoya Disease

  • Hyun-Seung Kang
  • Kyu-Chang Wang

Abstract

Single nucleotide polymorphisms (SNPs) are unique genetic differences between individuals that can contribute to disease susceptibility. Although more than 12 million SNPs have been identified, most of them are not associated with disease susceptibility [1]. Moyamoya disease (MMD) is more common in Asian populations; however, we do not know the reason for this. Genetic studies using SNPs may provide the answer. For example, an SNP in the promoter region of the tissue inhibitor of metalloproteinase 2 gene (TIMP2) is related to the occurrence of familial MMD [2]. High-throughput SNP genotyping may be fruitful in this field of research.

Keywords

Single Nucleotide Polymorphism Disease Susceptibility Moyamoya Disease Nonsynonymous SNPs Single Base Change 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Voisey J, Morris CP (2008) SNP technologies for drug discovery: a current review. Curr Drug Discov Technol 5:230–235PubMedCrossRefGoogle Scholar
  2. 2.
    Kang HS, Kim SK, Cho BK et al (2006) Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease. Neurosurgery 58:1074–1080PubMedCrossRefGoogle Scholar
  3. 3.
    Brookes AJ (1999) The essence of SNPs. Gene 234:177–186PubMedCrossRefGoogle Scholar
  4. 4.
    Holliday R, Grigg GW (1993) DNA methylation and mutation. Mutat Res 285:61–67PubMedCrossRefGoogle Scholar
  5. 5.
    Kondrashov AS (1995) Contamination of the genome by very slightly deleterious mutations: why have we not died 100 times over? J Theor Biol 175:583–594PubMedCrossRefGoogle Scholar
  6. 6.
    Crow JF (1995) Spontaneous mutation as a risk factor. Exp Clin Immunogenet 12:121–128PubMedGoogle Scholar
  7. 7.
    Li W, Sadler LA (1991) Low nucleotide diversity in man. Genetics 129:513–523PubMedGoogle Scholar
  8. 8.
    Chorley BN, Wang X, Campbell MR et al (2008) Discovery and verification of functional single nucleotide polymorphisms in regulatory genomic regions: current and developing technologies. Mutat Res 659:147–157PubMedCrossRefGoogle Scholar
  9. 9.
    Ikeda H, Sasaki T, Yoshimoto T et al (1999) Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet 64:533–537PubMedCrossRefGoogle Scholar
  10. 10.
    Inoue TK, Ikezaki K, Sasazuki T et al (2000) Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol 15:179–182PubMedCrossRefGoogle Scholar
  11. 11.
    Yamauchi T, Tada M, Houkin K et al (2000) Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 31:930–935PubMedCrossRefGoogle Scholar
  12. 12.
    Sakurai K, Horiuchi Y, Ikeda H et al (2004) A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet 49:278–281PubMedCrossRefGoogle Scholar
  13. 13.
    Mineharu Y, Liu W, Inoue K et al (2008) Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology 70:2357–2363PubMedCrossRefGoogle Scholar
  14. 14.
    Fujimura M, Watanabe M, Narisawa A et al (2009) Increased expression of serum matrix metallo-proteinase-9 in patients with moyamoya disease. Surg Neurol (In press)Google Scholar
  15. 15.
    Guo DC, Papke CL, Tran-Fadulu V et al (2009) Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and moyamoya disease, along with thoracic aortic disease. Am J Hum Genet 84:617–627PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  1. 1.Department of NeurosurgerySeoul National University Hospital, Seoul National University College of MedicineJongno-guRepublic of Korea
  2. 2.Division of Pediatric Neurosurgery, Pediatric Clinical Neuroscience CenterSeoul National University Children's Hospital, Seoul National University College of MedicineJongno-guRepublic of Korea

Personalised recommendations